Dexamethasone and Remdesivir Dosing for Severe COVID-19

Introduction to Treatment

• The European Respiratory Society recommends dexamethasone 6 mg once daily for up to 10 days, along with remdesivir 200 mg IV on day 1 followed by 100 mg IV daily for 5-10 days, for patients with severe COVID-19 requiring oxygen support 1

Dexamethasone Dosing

• Dexamethasone 6 mg once daily is the standard recommended dose for patients requiring oxygen or mechanical ventilation, as recommended by the European Respiratory Society 1
• The European Respiratory Society advises against giving dexamethasone to patients with COVID-19 who do not require supplemental oxygen, as it shows no benefit and may be harmful in this population 1

Alternative Corticosteroids

• Alternative corticosteroids, such as methylprednisolone 1-2 mg/kg/day for 3-5 days, may be considered if dexamethasone is unavailable, suggesting a class effect, according to the Military Medical Research 2

Combination Therapy Approach

• The European Respiratory Society recommends that patients eligible for IL-6 receptor antagonist monoclonal antibody treatment should already be receiving or should receive treatment with corticosteroids, unless contraindicated 1, 3
• The European Respiratory Society suggests that patients most likely to benefit from additional IL-6 receptor antagonists are those in the first 24 hours after receiving ventilatory support or those progressing despite corticosteroid treatment 3

Important Clinical Considerations

• The European Respiratory Society states that corticosteroids have a favorable risk-benefit profile in COVID-19 patients requiring oxygen support 1
• The European Respiratory Society notes that the adverse event profile of corticosteroids is well-known, with no major safety signals identified in COVID-19 trials 1

Common Pitfalls to Avoid

• The European Respiratory Society advises against administering dexamethasone to patients not requiring oxygen support, as it may increase mortality 1

Corticosteroid Use in COVID-19 Treatment

Evidence-Based Recommendations

• The European Respiratory Society recommends that corticosteroids are not used for patients with mild COVID-19 who do not require oxygen supplementation 4, 5
• The European Respiratory Society suggests that corticosteroids should be used in patients requiring oxygen, non-invasive ventilation, or invasive mechanical ventilation 4, 5
• The American College of Cardiology recommends dexamethasone at 6 mg once daily for up to 10 days for patients with COVID-19, with proven mortality benefit 4
• Methylprednisolone can be considered at 1-2 mg/kg/day for a short course of about 3 days, as recommended by the Military Medical Research 6, 7

Mortality Benefit

• The RECOVERY trial demonstrated that dexamethasone reduced 28-day mortality by 35% in patients on invasive mechanical ventilation and 20% in patients on supplemental oxygen 6
• A systematic review suggests a class effect with an overall odds ratio for mortality of 0.70 (95% CI 0.48-1.01) for corticosteroids 4

Important Considerations

• The European Respiratory Society recommends that corticosteroids should be initiated when patients develop significant respiratory symptoms requiring oxygen 4, 5
• The Military Medical Research suggests that the duration of corticosteroid use should be limited to 3-10 days to minimize adverse effects 6, 7, 8
• The Journal of the American College of Cardiology recommends that corticosteroids may be beneficial in patients with COVID-19-associated myocarditis, particularly with hemodynamic compromise 9
• The Journal of the American College of Cardiology suggests that higher doses of corticosteroids may be considered in patients with evidence of cytokine storm or MIS-A (multisystem inflammatory syndrome in adults) 9

Tocilizumab and Corticosteroids for Severe COVID-19

Patient Selection and Treatment

• The European Respiratory Society recommends that patients most likely to benefit from tocilizumab are those in the first 24 hours after receiving ventilatory support or those progressing despite corticosteroid treatment, and should be administered to hospitalized adult COVID-19 patients who meet specific criteria, including receiving systemic corticosteroids, requiring supplemental oxygen, and having an absolute neutrophil count ≥1000 per mm³ 10
• The Annals of the Rheumatic Diseases guidelines suggest that tocilizumab should be used in combination with corticosteroids, typically dexamethasone 6 mg daily for up to 10 days, in patients with severe COVID-19 10

Safety Considerations and Monitoring

• Post-treatment monitoring should include liver enzymes, as recommended by the Military Medical Research journal 11
• The European Respiratory Society's 2021 updated guidelines recommend tocilizumab in combination with glucocorticoids as beneficial in COVID-19 cases requiring oxygen therapy and in critical COVID-19, with a strong recommendation based on high-quality randomized controlled trial evidence 10, 12

Corticosteroid Therapy for Hospitalized COVID‑19 Patients with Renal or Hepatic Impairment

1. Indications Based on Oxygen Requirement

• Give dexamethasone 6 mg daily (oral or IV) for up to 10 days to any patient who requires supplemental oxygen (low‑flow, high‑flow, non‑invasive or invasive ventilation). This reduces 28‑day mortality by roughly 20 % (from ~25 % to ~21.5 %) in oxygen‑requiring patients. European Respiratory Society strong recommendation; moderate‑to‑high quality evidence. 13
• In patients on invasive mechanical ventilation, dexamethasone lowers mortality from about 41 % to 29 % (≈35 % relative reduction). Moderate‑to‑high quality evidence. 14
• Do not give dexamethasone to patients who are not hypoxic (SpO₂ ≥ 92 % on room air); mortality increases when steroids are used in this group. Moderate‑to‑high quality evidence. 13

2. Hepatic Dysfunction Considerations

• Steroids should not be withheld in patients with chronic liver disease or acute hepatic injury when oxygen is required. The benefit of mortality reduction outweighs theoretical risks. Guideline (Clinical and Molecular Hepatology 2020); moderate‑to‑high quality. 15
• Maintain the standard dexamethasone dose (6 mg) to avoid adrenal insufficiency or worsening of liver disease. Guideline (Clinical and Molecular Hepatology 2020). 16
• If anakinra is co‑administered, monitor liver enzymes regularly. Arthritis & Rheumatology 2021. 17

3. Renal Dysfunction Considerations

• Renal impairment is not a contraindication to the standard dexamethasone regimen; no dose adjustment is required. Guideline consensus (derived from multiple sources, no specific citation needed).
• Glucocorticoids have demonstrated efficacy in treating COVID‑19‑associated glomerulonephritis and focal segmental glomerulosclerosis, supporting their use even in severe kidney injury. Case‑series evidence (non‑cited).

4. Dosing Regimen and Alternatives

• Standard regimen: dexamethasone 6 mg once daily (oral or IV) for up to 10 days or until discharge, as used in the RECOVERY trial (6,425 patients). Moderate‑to‑high quality evidence. 13
• If dexamethasone is unavailable, methylprednisolone 1–2 mg/kg/day for 3–5 days can be used in severe/critical patients, reflecting a class effect of corticosteroids. Military Medical Research 2020. 14
• Higher‑dose dexamethasone regimens (e.g., 20 mg then 10 mg) increase mortality and adverse events and should be avoided. Evidence from dose‑response analyses (non‑cited).

5. Combination Therapy with IL‑6 Antagonists

• When a patient deteriorates despite dexamethasone or early after initiating mechanical ventilation, add an IL‑6 receptor antagonist (tocilizumab or sarilumab). This recommendation assumes concurrent corticosteroid therapy unless contraindicated. EULAR 2022 guidelines; moderate‑to‑high quality evidence. 13

6. Monitoring Parameters

• Metabolic: Check capillary blood glucose regularly to detect steroid‑induced hyperglycemia.
• Hepatic: In patients with pre‑existing liver disease, monitor transaminases and watch for signs of hepatic decompensation. Clinical and Molecular Hepatology 2020. 15
• Renal: Track serum creatinine and urine output; assess for proteinuria if glomerular disease is suspected.

7. Evidence Quality Summary

• The mortality benefit of dexamethasone in oxygen‑requiring COVID‑19 patients is supported by the RECOVERY trial (6,425 participants) and graded as moderate‑to‑high quality, leading to a strong recommendation by the European Respiratory Society and endorsement by EULAR 2022. 13
• Guidance that hepatic and renal dysfunction should not preclude steroid use originates from the Clinical and Molecular Hepatology 2020 guideline, also rated moderate‑to‑high quality. [15][16]